MICHAEL I NERENBERG, MD
Medical Practice at Carmel Mountain Rd, San Diego, CA
License number
California G68545
Category
Medical Practice
Type
Cytopathology
License number
California G68545
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
2
3398 Carmel Mountain Rd, San Diego, CA 92121
PO Box 10076, Van Nuys, CA 91410
PO Box 10076, Van Nuys, CA 91410
Phone
(858) 523-5003
(805) 578-8300
(805) 578-8950 (Fax)
(805) 578-8300
(805) 578-8950 (Fax)
Personal information
See more information about MICHAEL I NERENBERG at radaris.comName
Address
Phone
4321 Cm D Diamante, San Diego, CA 92121
6310 Nancy Ridge Dr, San Diego, CA 92121
8178 Gilman Ct, La Jolla, CA 92037
La Jolla, CA
205 Ocean View Ave, Del Mar, CA 92014
Professional information
Dr. Michael I Nerenberg, San Diego CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
3398 Carmel Mountain Rd, San Diego 92121
(858) 523-5003 (Phone)
(858) 523-5003 (Phone)
Certifications:
Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Yale University
Graduated: 1981
Yale University
Graduated: 1981
Method For Enhancing The Hybridization Efficiency Of Target Nucleic Acids Using A Self-Addressable, Self-Assembling Microelectronic Device
US Patent:
6518022, Feb 11, 2003
Filed:
Nov 22, 1999
Appl. No.:
09/444539
Inventors:
Ronald G. Sosnowski - Coronado CA
William F. Butler - Carlsbad CA
Eugene Tu - San Diego CA
Michael I. Nerenberg - San Diego CA
Michael J. Heller - Encinitas CA
Carl F. Edman - San Diego CA
William F. Butler - Carlsbad CA
Eugene Tu - San Diego CA
Michael I. Nerenberg - San Diego CA
Michael J. Heller - Encinitas CA
Carl F. Edman - San Diego CA
Assignee:
Nanogen, Inc. - San Diego CA
International Classification:
C12Q 168
US Classification:
435 6, 422 50, 422 681
Abstract:
A self-addressable, self-assembling microelectronic device is designed and fabricated to actively carry out and control multi-step and multiplex molecular biological reactions in microscopic formats. These reactions include nucleic acid hybridizations, antibody/antigen reactions, diagnostics, and biopolymer synthesis. The device can be fabricated using both microlithographic and micro-machining techniques. The device can electronically control the transport and attachment of specific binding entities to specific microlocations. The specific binding entities include molecular biological molecules such as nucleic acids and polypeptides. The device can subsequently control the transport and reaction of analytes or reactants at the addressed specific microlocations. The device is able to concentrate analytes and reactants, remove non-specifically bound molecules, provide stringency control for DNA hybridization reactions, and improve the detection of analytes. The device can be electronically replicated.
Suppression Of Nuclear Factor- B Dependent Processes Using Oligonucleotides
US Patent:
6498147, Dec 24, 2002
Filed:
Aug 20, 1993
Appl. No.:
08/110161
Inventors:
Michael I. Nerenberg - San Diego CA
Isao Kitajima - San Diego CA
Isao Kitajima - San Diego CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 3170
US Classification:
514 44, 536 231, 536 245
Abstract:
Antisense oligonucleotides which hybridize with nuclear factor- B(NF- B) mRNA and methods of using these oligonucleotides.
Methods And Procedures For Molecular Biological Analysis And Diagnostics
US Patent:
6051380, Apr 18, 2000
Filed:
Dec 5, 1997
Appl. No.:
8/986065
Inventors:
Ronald G. Sosnowski - Coronado CA
William F. Butler - Carlsbad CA
Eugene Tu - San Diego CA
Michael I. Nerenberg - San Diego CA
Michael J. Heller - Encinitas CA
Carl F. Edman - San Diego CA
William F. Butler - Carlsbad CA
Eugene Tu - San Diego CA
Michael I. Nerenberg - San Diego CA
Michael J. Heller - Encinitas CA
Carl F. Edman - San Diego CA
Assignee:
Nanogen, Inc. - San Diego CA
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
A self-addressable, self-assembling microelectronic device is designed and fabricated to actively carry out and control multi-step and multiplex molecular biological reactions in microscopic formats. These reactions include nucleic acid hybridizations, antibody/antigen reactions, diagnostics, and biopolymer synthesis. The device can be fabricated using both microlithographic and micro-machining techniques. The device can electronically control the transport and attachment of specific binding entities to specific microlocations. The specific binding entities include molecular biological molecules such as nucleic acids and polypeptides. The device can subsequently control the transport and reaction of analytes or reactants at the addressed specific microlocations. The device is able to concentrate analytes and reactants, remove non-specifically bound molecules, provide stringency control for DNA hybridization reactions, and improve the detection of analytes. The device can be electronically replicated.
Self-Addressable Self-Assembling Microelectronic Integrated Systems, Component Devices, Mechanisms, Methods, And Procedures For Molecular Biological Analysis And Diagnostics
US Patent:
8114589, Feb 14, 2012
Filed:
Mar 22, 2007
Appl. No.:
11/726520
Inventors:
Ronald G. Sosnowski - Coronado CA, US
William F. Butler - Carlsbad CA, US
Eugene Tu - San Diego CA, US
Michael I. Nerenberg - San Diego CA, US
Michael J. Heller - Encinitas CA, US
Carl F. Edman - San Diego CA, US
William F. Butler - Carlsbad CA, US
Eugene Tu - San Diego CA, US
Michael I. Nerenberg - San Diego CA, US
Michael J. Heller - Encinitas CA, US
Carl F. Edman - San Diego CA, US
Assignee:
Gamida For Life B.V. - Rotterdam
International Classification:
C12Q 1/68, C12Q 1/00
US Classification:
435 6, 435 4
Abstract:
A method for electronically stabilizing hybridization of nucleic acids bound at a test site of a microelectronic device is described. First and second negatively charged nucleic acids are provided, the second nucleic acid being bound to the test site. A zwitterionic buffer having a conductance of less than 100 mS/cm is applied to the microelectronic device. A current is applied to the test site to positively bias the test site, such that the first negatively charged nucleic acid is transported to the positively biased test site having the bound the second negatively charged nucleic acid. At the test site, the first and second negatively charged nucleic acids hybridize. The zwitterionic buffer acquires a net positive charge under influence of the current, such that the positively charged zwitterionic buffer stabilizes the hybridization by reducing the repulsion between the first and second negatively charged nucleic acids.
Method For Enhancing The Hybridization Efficiency Of Target Nucleic Acids Using A Self-Addressable, Self-Assembling Microelectronic Device
US Patent:
2003019, Oct 9, 2003
Filed:
Jun 11, 2002
Appl. No.:
10/170172
Inventors:
Ronald Sosnowski - Coronado CA, US
William Butler - Carlsbad CA, US
Eugene Tu - San Diego CA, US
Michael Nerenberg - San Diego CA, US
Michael Heller - Encinitas CA, US
Carl Edman - San Diego CA, US
William Butler - Carlsbad CA, US
Eugene Tu - San Diego CA, US
Michael Nerenberg - San Diego CA, US
Michael Heller - Encinitas CA, US
Carl Edman - San Diego CA, US
Assignee:
Nanogen, Inc. - San Diego CA
International Classification:
C12Q001/68, G06F019/00, G01N033/48, G01N033/50
US Classification:
435/006000, 702/020000
Abstract:
A self-addressable, self-assembling microelectronic device is designed and fabricated to actively carry out and control multi-step and multiplex molecular biological reactions in microscopic formats. These reactions include nucleic acid hybridizations, antibody/antigen reactions, diagnostics, and biopolymer synthesis. The device can be fabricated using both microlithographic and micro-machining techniques. The device can electronically control the transport and attachment of specific binding entities to specific microlocations. The specific binding entities include molecular biological molecules such as nucleic acids and polypeptides. The device can subsequently control the transport and reaction of analytes or reactants at the addressed specific microlocations. The device is able to concentrate analytes and reactants, remove non-specifically bound molecules, provide stringency control for DNA hybridization reactions, and improve the detection of analytes. The device can be electronically replicated.
Suppression Of Nuclear Factor-Κb Dependent Processes Using Oligonucleotides
US Patent:
7268121, Sep 11, 2007
Filed:
Dec 24, 2002
Appl. No.:
10/328861
Inventors:
Michael I. Nerenberg - San Diego CA, US
Isao Kitajima - San Diego CA, US
Isao Kitajima - San Diego CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 31/70, C07H 21/02, C07H 21/04, C12N 5/00
US Classification:
514 44, 536 231, 536 241, 536 245, 4353201
Abstract:
Antisense oligonucleotides which hybridize with nuclear factor-κB(NF-κB) mRNA and methods of using these oligonucleotides.
Suppression Of Nuclear Factor-Κb Dependent Processes Using Oligonucleotides
US Patent:
7704968, Apr 27, 2010
Filed:
Jul 30, 2007
Appl. No.:
11/888342
Inventors:
Michael I. Nerenberg - San Diego CA, US
Isao Kitajima - San Diego CA, US
Isao Kitajima - San Diego CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 31/70, C07H 21/02, C07H 21/04, C12Q 1/68
US Classification:
514 44, 435 6, 435375, 435377, 536 241, 536 245
Abstract:
Antisense oligonucleotides which hybridize with nuclear factor-κB (NF-κB) mRNA and methods of using these oligonucleotides.
Suppression Of Nuclear Factor-Κb Dependent Processes Using Oligonucleotides
US Patent:
7655635, Feb 2, 2010
Filed:
May 5, 2008
Appl. No.:
12/115373
Inventors:
Michael I. Nerenberg - San Diego CA, US
Isao Kitajima - San Diego CA, US
Isao Kitajima - San Diego CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C07H 21/02, C07H 21/04, A61K 31/70, C12Q 1/68, C12N 5/00
US Classification:
514 44, 536 231, 536 241, 536 245, 435 6, 435375, 435377
Abstract:
Antisense oligonucleotides which hybridize with nuclear factor-κB (NF-κB) mRNA and methods of using these oligonucleotides.